Rolapitant: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Rolapitant. Educational only — not medical advice.
Labeled uses
VARUBI® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Source: FDA labeling via NIH DailyMed (set a52896cd…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.